Development of anxiety in early Parkinson's disease: A clinical and biomarker study
European Journal of Neurology · 2023-09 · 30 (9) · 2661-2668
DOI: 10.1111/ene.15890 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 06.06.2023. Verfasst von Hanyuying Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Disorders of Excessive Somnolence. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Department of Health.
Abstract (Originalsprache)
Background
Anxiety affects approximately 40% of Parkinson's disease (PD) patients. However, little is known about its predictors and development over time.
Objective
To identify the clinical factors and biomarkers associated with development of anxiety in patients with newly diagnosed PD, and to test which risk factors predict increases in anxiety over time.
Methods
Data from the Parkinson's Progression Markers Initiative (PPMI) were utilized. The primary outcome was the State–Trait Anxiety Inventory (STAI). Covariates were demographics, motor and non‐motor symptoms, cognitive functions, dopamine transporter imaging data, and cerebrospinal fluid (CSF) biomarkers. We examined the association of risk factors at baseline and over 4 years with changes in anxiety scores over time.
Results
A total of 252 patients met the inclusion criteria (mean age: 61.36 years, SD 9.53). At year 4, 42 patients had developed anxiety. Baseline predictors of increase in anxiety scores were greater autonomic dysfunction, dysexecutive function, CSF t‐tau levels, excessive daytime sleepiness, and lower olfactory function scores but not motor scores. Over 4 years, change in anxiety scores correlated with deterioration in overall cognitive function, excessive daytime sleepiness, as well as depression and disability, and to a lesser degree worsening of Movement Disorder Society‐Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) motor scores and caudate dopaminergic uptake changes.
Conclusions
These findings suggest that development of anxiety in PD is not primarily based on a dopaminergic deficit in the basal ganglia but related to non‐dopaminergic or extrastriatal pathology. Early dysexecutive function predicts development of anxiety but increase in anxiety levels correlates most strongly with more global cognitive decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
- School of Pharmacy, UCL, London, UK.
ORCID-Profile: Hanyuying Wang, Yibo Zhao, Anette Schrag
Förderung
- Department of Health
Zitieren
APA
Wang, H., Zhao, Y., & Schrag, A. (2023). Development of anxiety in early Parkinson's disease: A clinical and biomarker study. European Journal of Neurology, 30(9), 2661-2668. https://doi.org/10.1111/ene.15890
Vancouver
Wang H, Zhao Y, Schrag A. Development of anxiety in early Parkinson's disease: A clinical and biomarker study. European Journal of Neurology. 2023;30(9):2661-2668. doi:10.1111/ene.15890
BibTeX
@article{Wang2023,
author = {Wang, Hanyuying and Zhao, Yibo and Schrag, Anette},
title = {Development of anxiety in early Parkinson's disease: A clinical and biomarker study},
journal = {European Journal of Neurology},
year = {2023},
volume = {30},
number = {9},
pages = {2661--2668},
doi = {10.1111/ene.15890}
}
EUVIMED